Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
07:20pm, Wednesday, 31'st Jul 2024
Glaukos (GKOS) came out with a quarterly loss of $0.52 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.
7 Leading MedTech Stocks for Next-Gen Health Solutions
02:30pm, Wednesday, 31'st Jul 2024
While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of Me
Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?
02:35pm, Tuesday, 30'th Jul 2024
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:07am, Wednesday, 24'th Jul 2024
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
12:30pm, Monday, 22'nd Jul 2024
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
09:05am, Wednesday, 10'th Jul 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
08:40am, Wednesday, 03'rd Jul 2024
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
01:50pm, Thursday, 27'th Jun 2024
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar?
04:20am, Thursday, 27'th Jun 2024
Glaukos (GKOS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated
Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?
01:16pm, Wednesday, 05'th Jun 2024
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
02:56pm, Monday, 03'rd Jun 2024
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos Announces Participation in Upcoming Investor Conferences
07:00am, Tuesday, 28'th May 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
National Bank of Canada FI Takes $46,000 Position in Glaukos Co. (NYSE:GKOS)
05:06am, Monday, 20'th May 2024
National Bank of Canada FI bought a new stake in Glaukos Co. (NYSE:GKOS – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commiss
Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock?
01:21pm, Tuesday, 14'th May 2024
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
